Latest Animal Health News

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.

Apiam Animal Health has officially become a wholly owned subsidiary of Adamantem Capital's entities following a scheme of arrangement, with shareholders receiving a special dividend and a mix of cash and shares. The company will soon be delisted from the ASX.

Shares of Apiam Animal Health Limited (ASX – AHX) have been suspended from trading following court approval of its acquisition by entities controlled by Adamantem Capital Fund II. This marks a significant ownership change for the animal health company.

Apiam Animal Health has secured court approval for its corporate scheme, paving the way for a fully franked special dividend payment next month.

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

Apiam Animal Health Limited has announced a special fully franked dividend of AUD 0.10 per share, with payment scheduled for mid-February 2026. Notably, the company has suspended its dividend reinvestment plan for this payout.

Apiam Animal Health has announced a fully franked special dividend of 10 cents per share, payable before the completion of its proposed acquisition by Adamantem Capital entities. The dividend is conditional on the scheme’s effectiveness and offers shareholders potential tax benefits through franking credits.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Apiam Animal Health shareholders have overwhelmingly approved the proposed acquisition by Adamantem Capital-controlled entities, clearing a critical hurdle for the $500 million deal.

Apiam Animal Health shareholders convened on 3 February 2026 to vote on a scheme of arrangement proposing acquisition by Adamantem Capital Fund II, with the board unanimously recommending approval. The scheme offers $0.87 cash per share or scrip alternatives, pending final court approval.